Bioanalysis Testing Solutions

In a consortium led by the Jenner Institute, Oxford University, SGS has joined forces with specialists in infectious diseases, research and innovation, and pharmaceuticals to rapidly develop, scale-up and produce a potential vaccine called ChAdOx1 nCov-19

Bringing a compound from the laboratory to the market is a long and winding road with a great number of scientific, safety and regulatory challenges. SGS has been offering high quality analytical testing and clinical research services to support drug research, registration and production. 
SGS leverages its conveniently located network of laboratories and clinical trial facilities present in North America, Europe and Asia-Pacific, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. 
Our experts provide effective and efficient testing solutions for analytical development, biologics characterization, biosafety and quality control, as well as clinical research services. We perform a variety of tests that are bespoke, client-specific and support the full clinical development, from Phase I First-in-Human trials in our Clinical Pharmacology Units to Phase II and Phase III studies in patients.

SGS is pleased to announce the signing of an agreement with AstraZeneca for the provision of safety, quality control and analytical testing services in support of AZD1222 – a COVID-19 vaccine candidate co-invented by the University of Oxford and its spin-out company, Vaccitech and licensed by AstraZeneca.

SGS Life Sciences has considerable expertise in the method development of nitrosamine determination in pharmaceutical products. SGS has established a specific method for NDMA which can be applied to various different matrices. Alternatively, a platform method, based on trace-level detection by LC-MSMS, is also available and provides rapid and simultaneous determination of up to ten different, targeted nitrosamines. Although with more limited application, the SGS network is also able to support specialist methodologies such as GC-MSMS. Our experience in optimizing extraction procedures allows application of these methods to drug products, API’s, and raw materials. 

Telecommuting and online commerce has been with us for some time and works seamlessly in many industries, but the current state of events has forced companies to apply remote management to other areas that have historically been considered "hands-on" job functions.

A full package of Biologics testing services to cGMP standards from early phase characterisation including Biosafety to Quality Control release testing enabling you to outsource your biologics.

Following its emergence earlier this year, the novel coronavirus (SARS-CoV-2) has spread rapidly and snowballed into a pandemic. Everyone – citizens, businesses, and governments – yearns for life to go back to normal soon.

Delivering a product from discovery to the market is a long and often difficult process filled with a great number of scientific, safety and regulatory challenges. From early discovery to final product release, SGS offers a broad portfolio of high quality, analytical chemistry services using advanced methods and instrumentation.


SGS leverages its conveniently located network of laboratories present in North America, Europe and Asia-Pacific, to deliver harmonized solutions to local markets as well as international pharmaceutical and biotechnology firms.

Our recognized experts assist in providing effective and efficient solutions for R&D, analytical development, and quality control testing, helping to expedite the molecule to market.

Life-saving medicines are heavily regulated during development, manufacture and distribution. To fulfill regulatory requirements, the biopharmaceutical industry is increasingly looking for independent service providers who can deliver comprehensive characterization solutions on one site. 
SGS’s global center of excellence for cell bank characterization & virus testing is located in the United Kingdom and provides services with ultimate reliability, highest GLP/cGMP quality & scientific expertise. 
As trailblazers in the development of the biosafety testing industry, our team in Glasgow have developed and validated novel nucleic acid technologies, such as real-time PCR, RAPD, Sequencing, Non
radioactive Southern Blotting, Next Generation Sequencing (NGS). For any of your biologics, we help you comply with the global regulatory guidelines and testing requirements.

SGS' integrated network of laboratories provides a wide range of essential services to support the fight against COVID-19. We provide established expertise and resources for all aspects of biopharmaceuticals characterization, from physico-chemical properties, to primary, secondary, and tertiary structures, as well as aggregation.
For more information, contact [email protected] or visit: https://www.sgs.com/lifescience.

Watch to find out more about how our Extractables & Leachables studies enable drug sponsors to quantify and identify the risks of potentially toxic leachable impurities migrating into a drug solution from container closure systems, processing equipment or packaging, to ensure patient safety and drug product efficacy. 
Visit https://www.sgs.com/en/life-sciences/ to find out more.

The presence of the #nitrosamine N-nitrosodimethylamine (#NDMA), in certain sartan APIs has resulted in several regulatory warnings and recalls of contaminated products. We have considerable expertise in the method development for detecting the presence of NDMA and other nitrosamines to help you to ensure product safety and comply with USFDA and EMA requirements.

For more information, contact [email protected] or visit: https://www.sgs.com/lifescience.

#Nitrosamine #DrugSafety #DrugDevelopment